How hypocretin agonists may improve the quality of wake in narcolepsy

Research output: Contribution to journal › Review › Research › peer-review

Standard

How hypocretin agonists may improve the quality of wake in narcolepsy. / Justinussen, Jessica L.; Egebjerg, Christine; Kornum, Birgitte R.

In: Trends in Molecular Medicine, Vol. 29, No. 1, 2023, p. 61-69.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Justinussen, JL, Egebjerg, C & Kornum, BR 2023, 'How hypocretin agonists may improve the quality of wake in narcolepsy', Trends in Molecular Medicine, vol. 29, no. 1, pp. 61-69. https://doi.org/10.1016/j.molmed.2022.10.008

APA

Justinussen, J. L., Egebjerg, C., & Kornum, B. R. (2023). How hypocretin agonists may improve the quality of wake in narcolepsy. Trends in Molecular Medicine, 29(1), 61-69. https://doi.org/10.1016/j.molmed.2022.10.008

Vancouver

Justinussen JL, Egebjerg C, Kornum BR. How hypocretin agonists may improve the quality of wake in narcolepsy. Trends in Molecular Medicine. 2023;29(1):61-69. https://doi.org/10.1016/j.molmed.2022.10.008

Author

Justinussen, Jessica L. ; Egebjerg, Christine ; Kornum, Birgitte R. / How hypocretin agonists may improve the quality of wake in narcolepsy. In: Trends in Molecular Medicine. 2023 ; Vol. 29, No. 1. pp. 61-69.

Bibtex

@article{74968c75a757417792e30bf429720424,
title = "How hypocretin agonists may improve the quality of wake in narcolepsy",
abstract = "Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy.",
keywords = "anxiety, attention, excessive daytime sleepiness treatment, hypocretin, narcolepsy, wake",
author = "Justinussen, {Jessica L.} and Christine Egebjerg and Kornum, {Birgitte R.}",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2023",
doi = "10.1016/j.molmed.2022.10.008",
language = "English",
volume = "29",
pages = "61--69",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Ltd. * Trends Journals",
number = "1",

}

RIS

TY - JOUR

T1 - How hypocretin agonists may improve the quality of wake in narcolepsy

AU - Justinussen, Jessica L.

AU - Egebjerg, Christine

AU - Kornum, Birgitte R.

N1 - Publisher Copyright: © 2022 Elsevier Ltd

PY - 2023

Y1 - 2023

N2 - Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy.

AB - Excessive daytime sleepiness (EDS) is a complex symptom characterized by a strong urge to sleep during daytime accompanied by problems such as attention deficits, anxiety, and lower cognitive performance. The efficacy of treatments for EDS is determined by their ability to decrease sleepiness, and less attention has been given to the effects these compounds have on the quality of the wake itself. Hypocretin (HCRT; orexin) signalling is implicated in narcolepsy, and hypocretin receptor 2 (HCRTR2) agonists are in clinical trials for treating EDS in narcolepsy. Here, we review preclinical research to determine how HCRTR2 agonists may affect attention and anxiety compared with other EDS treatment strategies. We conclude that such compounds may improve not only the quantity but also the quality of wake, and we hope that they will create opportunities for more nuanced treatment strategies in narcolepsy.

KW - anxiety

KW - attention

KW - excessive daytime sleepiness treatment

KW - hypocretin

KW - narcolepsy

KW - wake

U2 - 10.1016/j.molmed.2022.10.008

DO - 10.1016/j.molmed.2022.10.008

M3 - Review

C2 - 36400667

AN - SCOPUS:85141961866

VL - 29

SP - 61

EP - 69

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -

ID: 326841807